Loading
A phase 1/2 trial of VLS-1488 in non-small-cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, ovarian cancer, sarcomas and endometrial cancer, run by Volastra Therapeutics, Inc., now recruiting.
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer is a phase 1/2 interventional study registered as NCT05902988 by Volastra Therapeutics, Inc., with 200 participants planned, started 2023-10-18 and due to reach its primary completion in 2026-06. Interventions recorded: VLS-1488.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.